Skip Nav Destination
1-12 of 12
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD
Blood (2019) 134 (Supplement_1): 1311.
Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission
H. Moses Murdock, BS, Haesook T. Kim, PhD, Bryan Hambley, MD, Pankit Vachhani, MD, Nathan Denlinger, MS, DO, Shannon H. Gier, BS, Christina Cho, MD, Miguel-Angel Perales, MD, John Koreth, MBBS, DPhil, Vincent T. Ho, Robert J. Soiffer, MD, Shannon R. McCurdy, MD, Martin Carroll, MD, Sumithira Vasu, MDMBBS, Eunice S. Wang, MD, Lukasz P. Gondek, MDPhD, Steven Devine, MD, Edwin P. Alyea, III, MD, Christopher J. Gibson, MD, R. Coleman Lindsley, MD PhD
Blood (2019) 134 (Supplement_1): 48.
BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Sumithira Vasu, MDMBBS, Nelli Bejanyan, MD, Steven Devine, MD, Elizabeth Krakow, MDMSc, Elizabeth Krakow, MD, Brent Logan, PhD, Leo Luznik, MD, Brittany K Ragon, MD, Emma Barrett, MD, Joe Shan, MPH, BS, Richard E. Champlin, MD
Blood (2019) 134 (Supplement_1): 1955.
Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor
John F. DiPersio, MD PhD, Jonathan Hoggatt, PhD, Steven Devine, MD, Lukasz Biernat, MD, Haley Howell, BS, BA, Veit Schmelmer, PhD, Jason R. Neale, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Kevin A. Goncalves, PhD, Glen D. Raffel, MD PhD, Patrick C. Falahee, PhD, Dwight M. Morrow, PhD, John C. Davis, Jr., MD MPH, MS
Blood (2019) 134 (Supplement_1): 1961.
Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials
Polina Shindiapina, MD PhD, Maciej Pietrzak, PhD, Michal Seweryn, PhD, Eric McLaughlin, MS, Xiaoli Zhang, PhD, Mateusz Makowski, PhD, Justin Lyberger, Hsiaochi Chang, Elshafa Hassan Ahmed, DVM, PhD, Alexander Prouty, BS, Rebecca Pearson, Rhonda Kitzler, Jennifer Le-Rademacher, PhD, Richard F. Little, MD MPH, Gorgun Akpek, MD, Ernesto Ayala, MD, Steven Devine, MD, Ariela Noy, MD, Lawrence D Kaplan, MD, Uday Popat, MD, Jack W. Hsu, MD, Lawrence E Morris, MD, Adam M. Mendizabal, MS, Craig C Hofmeister, MDMPH, William Wachsman, MD PhD, Stephen J Forman, MD, Willis H. Navarro, MD, Joseph C. Alvarnas, MD, Richard F. Ambinder, MD, Gregory K. Behbehani, MD PhD, Gerard Lozanski, MD, Robert A Baiocchi, MD PhD
Blood (2019) 134 (Supplement_1): 4525.
BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML
Mark J. Levis, MD, Mehdi Hamadani, MD, Brent R. Logan, Matt Rosales, David Delgado, Erkut Bahceci, Steven Devine, MD, Mary M. Horowitz, Yi-Bin Chen
Blood (2019) 134 (Supplement_1): 4602.
Impact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of I n Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies
Robert J Soiffer, MD, Jennifer LeRademacher, PhD, Vincent T Ho, MD, Fangyu Kan, MD, MS, Andrew Artz, MD, MS, Richard Champlin, Steven Devine, MD, Hillard M. Lazarus, MD, FACP, David I Marks, MB, BS, PHD, David Porter, MD, Edmund K. Waller, MD, PhD, Mary M. Horowitz, MD, MS, Mary Eapen, MBBS
Blood (2010) 116 (21): 2305.
Transplantation without Hemolysis in a Kell Antigen Positive Patient Undergoing Peripheral Hematopoietic Stem Cell Transplant from a Donor with Anti-Kell Antibodies.
Blood (2006) 108 (11): 4137.
A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.
Kenneth B. Miller, MD, Nelson J. Chao, MD, Hans A. Messner, MD,PhD, Steven C. Goldstein, MD, Vijay Reddy, MD,PhD, William Vaughan, MD, Steven Devine, MD, Scott D. Rowley, MD, Ned Waller, MD,PhD, Marcel Devetten, MD, Gary J. Schiller, MD
Blood (2006) 108 (11): 5369.
A Randomized, Double Blind Trial, of Hydroxychloroquine for the Prevention of Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation.
Tom Fong, MD, Kim Trinkaus, PhD, Douglas R. Adkins, MD, Ravi Vij, MD, Steven Devine, MD, Michael Tomasson, MD, Lawrence T. Goodnough, MD, Timothy Graubert, MD, Shalini Shenoy, MD, John F. DiPersio, MD, PhD, Hanna J. Khoury, MD
Blood (2005) 106 (11): 1800.
AMD3100 + G-CSF Improves Hematopoietic Progenitor Cell (HPC) Collection in Patients with Hodgkin’s Disease (HD).
Blood (2005) 106 (11): 1979.
Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.
David Marin, MD, Michael Mauro, MD, John Goldman, MD, Brian Druker, MD, Steven Devine, MD, Richard E. Clark, MD, Ronald Paquette, MD, Asad Bashey, MD, Martin S. Tallman, MD, April Dovholuk, Axel Hoos, MD, PhD, Pramod Srivastava, PhD
Blood (2005) 106 (11): 1094.